ArticleSurgical endoscopy2026
Association between endoscopic sphincterotomy and the development of hepatopancreatobiliary cancer.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy (ES) has been hypothesized to increase the risk of hepatopancreatobiliary (HPB) cancer, but prior studies have shown conflicting results. This study aimed to determine whether ERCP with ES is associated with the longitudinal development of HPB cancer.
methodsThis matched cohort study conducted from 2010 to 2022 used linked medical record data from clinics, hospitals, and other facilities in Southeast Minnesota and Southwest Wisconsin. A total of 188,243 patients were included: 4003 with cholelithiasis or choledocholithiasis who underwent ERCP with ES (Group A), 18,816 underwent cholecystectomy only (Group B), 20,593 received no procedures (Group C), as well as 144,831 healthy controls without cholelithiasis or choledocholithiasis who did not undergo ERCP or cholecystectomy (Group D). Incidence of and time to development of HPB cancer were compared in groups A, B, and C to healthy controls in group D.
resultsThe incidence of HPB cancer was 1.2% in Group A, 0.7% in Group B, 0.9% in Group C, and 0.6% in controls. The hazard ratio (HR) for developing HPB cancer compared to controls was highest in the ERCP group (HR 1.64, 95% CI: 1.22-2.22, p = 0.001), followed by the non-procedural group (HR 1.32, 95% CI: 1.12-1.56, p < 0.001). The lowest risk was in the cholecystectomy without ERCP group (HR 1.20, 95% CI: 0.99-1.45, p = 0.06).
conclusionThis epidemiologic cohort study found that patients who underwent ERCP with ES exhibited a higher incidence of developing HPB cancer over time compared to patients who underwent cholecystectomy alone.
Indexed as
Identifiers
42448964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.